Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
VANI 
Vivani Medical Inc. (VANI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/12/2025: VANI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4
1 Year Target Price $4
| 0 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 67.33% | Avg. Invested days 40 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 12/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 98.49M USD | Price to earnings Ratio - | 1Y Target Price 4 |
Price to earnings Ratio - | 1Y Target Price 4 | ||
Volume (30-day avg) 2 | Beta 3.32 | 52 Weeks Range 0.91 - 1.92 | Updated Date 12/14/2025 |
52 Weeks Range 0.91 - 1.92 | Updated Date 12/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.45 |
Earnings Date
Report Date 2025-11-18 | When - | Estimate -0.095 | Actual -0.11 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -50.05% | Return on Equity (TTM) -265.02% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 114150517 | Price to Sales(TTM) - |
Enterprise Value 114150517 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.93 | Shares Outstanding 72952235 | Shares Floating 35432901 |
Shares Outstanding 72952235 | Shares Floating 35432901 | ||
Percent Insiders 39.82 | Percent Institutions 5.37 |
About Vivani Medical Inc.
Exchange NASDAQ | Headquaters Alameda, CA, United States | ||
IPO Launch date 2014-11-19 | Co-Founder, CEO & Director Dr. Adam Mendelsohn Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 37 | Website https://www.vivani.com |
Full time employees 37 | Website https://www.vivani.com | ||
Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease and medication non-adherence. Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in clinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature and subdermal GLP-1 implant in development for chronic weight management; and OKV-119, an exenatide implant for metabolic diseases in cats. The company is headquartered in Alameda, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.